<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Nalmefene" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Nalmefene</book-part-id>
      <title-group>
        <title>Nalmefene</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>3</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Naldemedine" document-type="chapter">Naldemedine</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Naloxegol" document-type="chapter">Naloxegol</related-object>
    </book-part-meta>
    <body>
      <sec id="Nalmefene.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Nalmefene.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Nalmefene is an opiate receptor antagonist which is used to treat acute opioid overdose and to help in the management of alcohol dependence and addictive behaviors. Nalmefene has not been linked to serum enzyme elevations during therapy or to clinically apparent liver injury.</p>
        </sec>
        <sec id="Nalmefene.Background">
          <title>Background</title>
          <p>Nalmefene (nal&#x02019; me feen) is a semisynthetic opiate receptor antagonist which is similar structurally to naltrexone and oxymorphone. Nalmefene is distinctive in having antagonist activity against all three types of opiate receptors &#x02013; &#x003bc;, &#x003ba; and &#x003b4;. When given intravenously or intramuscularly, nalmefene causes rapid onset of withdrawal symptoms in opioid dependent persons and has been used successfully to treat acute opioid overdose. It is also used to reverse opioid actions in the postoperative period. It has a longer duration of action than naloxone and better oral availability. Nalmefene was approved for use in the United States in 1995 as a therapy of opioid overdose. Oral formulations, which have been used to treat alcohol dependence and other addictive behaviors, have not been approved for this use in the United States. Nalmefene is available in solutions for injection in concentrations of 100 &#x003bc;g/mL (for postoperative use) and 1 mg/mL (for management of known of suspected opioid overdose) under the trade name Revex. Side effects of parenterally administered nalmefene in opioid dependent patients include mood changes, sweating, anxiety, restlessness, trembling, dizziness, flushing, headache, nausea, vomiting, cardiac tachyarrhythmias, seizures, chest pain and acute pulmonary edema&#x02014;symptoms of acute opioid withdrawal. In persons not taking opioids, nalmefene has minimal effects. Nalmefene is not a controlled substance, but its use is sometimes restricted to medical staff trained in emergency medicine or anesthesia.</p>
        </sec>
        <sec id="Nalmefene.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Therapy with nalmefene has not been linked to serum enzyme elevations or to idiosyncratic acute, clinically apparent liver injury. Nalmefene is extensively metabolized in the liver, but largely by glucuronidation rather than transformation to a different metabolite. Patients with opioid overdose often have underlying chronic liver diseases such as alcoholic liver disease, hepatitis B or C, but treatment with nalmefene does not appear to exacerbate those conditions.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
          <p>Drug Class: Opioid Antagonists; see also <related-object link-type="booklink" source-id="livertox" document-id="SubstanceAbuseTreatm" document-type="chapter">Substance Abuse Treatment Agents</related-object></p>
          <p>Other Drugs in the Class: <related-object link-type="booklink" source-id="livertox" document-id="Naloxegol" document-type="chapter">Naloxegol</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Naloxone" document-type="chapter">Naloxone</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Naltrexone" document-type="chapter">Naltrexone</related-object></p>
        </sec>
      </sec>
      <sec id="Nalmefene.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Nalmefene &#x02013; Revex&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Opioid Antagonists</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49fd02f8-12b8-460c-ae1f-f26738d86998">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Nalmefene.CHEMICAL_FORMULA_AND_STRUCTURE">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Nalmefene.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <tbody>
              <tr>
                <th id="hd_b_Nalmefene.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_b_Nalmefene.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">CAS REGISTRY NO.</th>
                <th id="hd_b_Nalmefene.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_b_Nalmefene.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
              <tr>
                <td headers="hd_b_Nalmefene.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Nalmefene HCl</td>
                <td headers="hd_b_Nalmefene.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135074883">58895-64-0</ext-link>
                </td>
                <td headers="hd_b_Nalmefene.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C21-H25-N-O3.Cl-H</td>
                <td headers="hd_b_Nalmefene.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135074883" document-id-type="sid" document-type="summary" object-id="135074883" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Nalmefene.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 24 March 2020</p>
        <ref-list id="Nalmefene.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Nalmefene.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Narcotic analgesics. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 710-11.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999; mentions that trials of naltrexone have reported serum aminotransferase elevations in up to 30% of recipients, an effect that appeared to be partially dose dependent; nalmefene not discussed).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Nalmefene.REF.larrey.2013">
            <mixed-citation publication-type="book">Larrey D, Ripault MP. Illegal and recreational compounds. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 456-7.<annotation><p><italic toggle="yes">(Review of hepatotoxicity discusses buprenorphine, an orally available morphine analogue, which has been linked to cases of severe acute liver injury, usually as a result of intravenous administration; nalmefene not discussed).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Nalmefene.REF.yaksh.2018">
            <mixed-citation publication-type="book">Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 355-86.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Nalmefene.REF.dixon.1987.233">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Dixon</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Gentile</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Hsu</surname>
                  <given-names>HB</given-names>
                </name>
                <name name-style="western">
                  <surname>Hsiao</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Howes</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Garg</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Weidler</surname>
                  <given-names>D</given-names>
                </name>
              </person-group>
              <article-title>Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist.</article-title>
              <source>J Clin Pharmacol</source>
              <year>1987</year>
              <volume>27</volume>
              <fpage>233</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Phase 1 study of safety of single injections and 7 day courses of nalmefene in different doses found no increases in serum aminotransferase levels).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3680580</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.kaplan.1993.187">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kaplan</surname>
                  <given-names>JL</given-names>
                </name>
                <name name-style="western">
                  <surname>Marx</surname>
                  <given-names>JA</given-names>
                </name>
              </person-group>
              <article-title>Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study.</article-title>
              <source>Ann Emerg Med</source>
              <year>1993</year>
              <volume>22</volume>
              <fpage>187</fpage>
              <lpage>90</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 53 patients with suspected opioid overdose who were treated with 1-10 boluses of either 0.5 and 1.0 mg of intravenous nalmefene, no serious adverse events were found; side effects possibly related to nalmefene were vomiting, dizziness and diarrhea).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8427429</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.mason.1994.1162">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Mason</surname>
                  <given-names>BJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Ritvo</surname>
                  <given-names>EC</given-names>
                </name>
                <name name-style="western">
                  <surname>Morgan</surname>
                  <given-names>RO</given-names>
                </name>
                <name name-style="western">
                  <surname>Salvato</surname>
                  <given-names>FR</given-names>
                </name>
                <name name-style="western">
                  <surname>Goldberg</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Welch</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Mantero-Atienza</surname>
                  <given-names>E</given-names>
                </name>
              </person-group>
              <article-title>A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.</article-title>
              <source>Alcohol Clin Exp Res</source>
              <year>1994</year>
              <volume>18</volume>
              <fpage>1162</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Controlled trial of 12 weeks of nalmefene or placebo in 21 alcohol dependent patients found no difference in laboratory measures during therapy, serum ALT levels decreasing in abstinent patients).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7847600</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.bergasa.1998.679">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bergasa</surname>
                  <given-names>NV</given-names>
                </name>
                <name name-style="western">
                  <surname>Schmitt</surname>
                  <given-names>JM</given-names>
                </name>
                <name name-style="western">
                  <surname>Talbot</surname>
                  <given-names>TL</given-names>
                </name>
                <name name-style="western">
                  <surname>Alling</surname>
                  <given-names>DW</given-names>
                </name>
                <name name-style="western">
                  <surname>Swain</surname>
                  <given-names>MG</given-names>
                </name>
                <name name-style="western">
                  <surname>Turner</surname>
                  <given-names>ML</given-names>
                </name>
                <name name-style="western">
                  <surname>Jenkins</surname>
                  <given-names>JB</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.</article-title>
              <source>Hepatology</source>
              <year>1998</year>
              <volume>27</volume>
              <fpage>679</fpage>
              <lpage>84</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Open label trial of nalmefene for 2-26 months in 14 patients with liver disease and pruritus found "no consistent effect of nalmefene on the severity of cholestasis, as assessed by routine serum biochemical markers").</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">9500694</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.kaplan.1999.42">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kaplan</surname>
                  <given-names>JL</given-names>
                </name>
                <name name-style="western">
                  <surname>Marx</surname>
                  <given-names>JA</given-names>
                </name>
                <name name-style="western">
                  <surname>Calabro</surname>
                  <given-names>JJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Gin-Shaw</surname>
                  <given-names>SL</given-names>
                </name>
                <name name-style="western">
                  <surname>Spiller</surname>
                  <given-names>JD</given-names>
                </name>
                <name name-style="western">
                  <surname>Spivey</surname>
                  <given-names>WL</given-names>
                </name>
                <name name-style="western">
                  <surname>Gaddis</surname>
                  <given-names>GM</given-names>
                </name>
                <name name-style="western">
                  <surname>Zhao</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Harchelroad</surname>
                  <given-names>FP</given-names>
                  <suffix>Jr</suffix>
                </name>
              </person-group>
              <article-title>Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose.</article-title>
              <source>Ann Emerg Med</source>
              <year>1999</year>
              <volume>34</volume>
              <fpage>42</fpage>
              <lpage>50</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Controlled trial of two doses of nalmefene vs naloxone in 118 patients with suspected opioid overdose found similar rates of response and adverse events; the most common ones attributed to nalmefene were vomiting, tachycardia, nausea and myoclonus).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">10381993</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.anton.2004.421">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Anton</surname>
                  <given-names>RF</given-names>
                </name>
                <name name-style="western">
                  <surname>Pettinati</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Zweben</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Kranzler</surname>
                  <given-names>HR</given-names>
                </name>
                <name name-style="western">
                  <surname>Johnson</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Bohn</surname>
                  <given-names>MJ</given-names>
                </name>
                <name name-style="western">
                  <surname>McCaul</surname>
                  <given-names>ME</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence.</article-title>
              <source>J Clin Psychopharmacol</source>
              <year>2004</year>
              <volume>24</volume>
              <fpage>421</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 270 recently abstinent alcohol dependent subjects treated with one of 3 doses of nalmefene or placebo for 12 weeks, side effects of nausea, dry mouth, insomnia, dizziness and confusion were more common in nalmefene treated patients; no mention of ALT and AST results).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15232334</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.reuben.2010.2065">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Reuben</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Koch</surname>
                  <given-names>DG</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>WM</given-names>
                </name>
                <collab>Acute Liver Failure Study Group</collab>
              </person-group>
              <article-title>Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.</article-title>
              <source>Hepatology</source>
              <year>2010</year>
              <volume>52</volume>
              <fpage>2065</fpage>
              <lpage>76</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none to nalmefene, naltrexone or other agents used to treated substance abuse).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20949552</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.van_den_brink.2013.570">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>van den Brink</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Aubin</surname>
                  <given-names>HJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Bladstr&#x000f6;m</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Torup</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Gual</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Mann</surname>
                  <given-names>K</given-names>
                </name>
              </person-group>
              <article-title>Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies.</article-title>
              <source>Alcohol Alcohol</source>
              <year>2013</year>
              <volume>48</volume>
              <fpage>570</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Retrospective analysis of 667 alcohol dependent patients treated with nalmefene or placebo on an as-needed basis for 6 months found decrease in average GGT and ALT values during the study, with greater decrease in nalmefene treated subjects).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23873853</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.bj_rnsson.2013.1419">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>ES</given-names>
                </name>
                <name name-style="western">
                  <surname>Bergmann</surname>
                  <given-names>OM</given-names>
                </name>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>HK</given-names>
                </name>
                <name name-style="western">
                  <surname>Kvaran</surname>
                  <given-names>RB</given-names>
                </name>
                <name name-style="western">
                  <surname>Olafsson</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland.</article-title>
              <source>Gastroenterology</source>
              <year>2013</year>
              <volume>144</volume>
              <fpage>1419</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, none of which were attributed to nalmefene or other opioid antagonists).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23419359</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.van_den_brink.2014.733">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>van den Brink</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000f8;rensen</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Torup</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Mann</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Gual</surname>
                  <given-names>A</given-names>
                </name>
                <collab>SENSE Study Group</collab>
              </person-group>
              <article-title>Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.</article-title>
              <source>J Psychopharmacol</source>
              <year>2014</year>
              <volume>28</volume>
              <fpage>733</fpage>
              <lpage>44</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 675 alcohol dependent patients treated with nalmefene (18 mg) or placebo once daily for 1 year, decreases in alcohol intake were greater with nalmefene at 1 year (but not 6 months), and there were no differences in the incidence of clinically relevant laboratory values between the 2 treatment groups&#x0201d; except in ALT and AST values, but specific differences were not described).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24671340</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hern&#x000e1;ndez</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bessone</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000e1;nchez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>di Pace</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Brahm</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zapata</surname>
                  <given-names>R, A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chirino</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, none were attributed to nalmefene or other opioid antagonists).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to nalmefene or other opioid antagonists).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.van_den_brink.2015.495">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>van den Brink</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Strang</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Gual</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000f8;rensen</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Jensen</surname>
                  <given-names>TJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Mann</surname>
                  <given-names>K</given-names>
                </name>
              </person-group>
              <article-title>Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.</article-title>
              <source>Expert Opin Drug Saf</source>
              <year>2015</year>
              <volume>14</volume>
              <fpage>495</fpage>
              <lpage>504</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1123 patients treated with &#x0201c;as needed&#x0201d; nalmefene and 824 with placebo for alcohol dependency in 3 controlled trials, adverse events more frequent with nalmefene included nausea [22 vs 6%], dizziness [18% vs 6%, insomnia [13% vs 5%] and headache [12% vs 8%], but not ALT or AST elevations above 3 times ULN [3.8% vs 3.9%] and there were no episodes of clinically apparent liver injury).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25652768</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.johansen.2017.e0183821">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Johansen</surname>
                  <given-names>KGV</given-names>
                </name>
                <name name-style="western">
                  <surname>Tarp</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Astrup</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Lund</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Pagsberg</surname>
                  <given-names>AK</given-names>
                </name>
                <name name-style="western">
                  <surname>Christensen</surname>
                  <given-names>R</given-names>
                </name>
              </person-group>
              <article-title>Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials.</article-title>
              <source>PLoS One</source>
              <year>2017</year>
              <volume>12</volume>
              <elocation-id>e0183821</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(Metaanalysis of 8 controlled trials found similar rates of serious adverse events and deaths in nalmefene vs placebo recipients but higher rates of discontinuation because of adverse events; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28850596</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.castera.2018.293">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Castera</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Stewart</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Gro&#x000df;kopf</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Brotons</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Brix Schou</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Steiniger Brach</surname>
                  <given-names>B</given-names>
                </name>
                <etal/>
                <collab>PICASO Study&#x000a0;Investigators</collab>
              </person-group>
              <article-title>Nalmefene, given as needed, in the routine treatment of patients with alcohol dependence: an interventional, open-label study in primary care.</article-title>
              <source>Eur Addict Res</source>
              <year>2018</year>
              <volume>24</volume>
              <fpage>293</fpage>
              <lpage>303</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 378 patients with alcohol dependency treated with open-label &#x0201c;as-needed&#x0201d; nalmefene, side effects included nausea (18%) and dizziness (18%), and one patient died of decompensated cirrhosis that was considered unrelated to the therapy and there were no other &#x0201c;clinically relevant changes&#x0201d; in laboratory values).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30485854</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.chaignot.2018.1239">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chaignot</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Zureik</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Rey</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Dray-Spira</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Coste</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Weill</surname>
                  <given-names>A</given-names>
                </name>
              </person-group>
              <article-title>Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165&#x000a0;334 patients between 2009 and 2015 in France.</article-title>
              <source>Pharmacoepidemiol Drug Saf</source>
              <year>2018</year>
              <volume>27</volume>
              <fpage>1239</fpage>
              <lpage>48</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Analysis of the French Health Insurance claims database of patients initiating alcohol use disorder therapies found an increased risk of hospitalization [+13%] and death [+31%] compared to exposure to approved drugs such as acamprosate, naltrexone and nalmefene).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30251424</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF20">
            <element-citation publication-type="journal">
              <article-title>Opioids for pain.</article-title>
              <source>Med Lett Drugs Ther</source>
              <year>2018</year>
              <volume>60</volume>
              <issue>1544</issue>
              <fpage>57</fpage>
              <lpage>64</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise review of the efficacy, safety and costs of opioids used for pain mentions that the 3 opioid antagonists that are used to treat opioid induced constipation-methylnaltrexone, naloxegol and nalmedine-have similar degrees of efficacy and toxicities).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">29664446</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.miyata.2019.697">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Miyata</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Takahashi</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Murai</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Tsuneyoshi</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Hayashi</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Meulien</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000f8;rensen</surname>
                  <given-names>P</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial.</article-title>
              <source>Psychiatry Clin Neurosci</source>
              <year>2019</year>
              <volume>73</volume>
              <fpage>697</fpage>
              <lpage>706</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 594 Japanese patients with alcohol dependency treated with as-needed nalmefene or placebo for 12 weeks, alcohol use was less with nalmefene treatment while adverse events were more frequent; although &#x0201c;there were no clinically significant laboratory findings&#x0201d;, one patient discontinued nalmefene therapy because of chronic hepatitis).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31298784</pub-id>
            </element-citation>
          </ref>
          <ref id="Nalmefene.REF.l_pezpelayo.2020.9">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>L&#x000f3;pez-Pelayo</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Zuluaga</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Caballeria</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Van den Brink</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Mann</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Gual</surname>
                  <given-names>A</given-names>
                </name>
              </person-group>
              <article-title>Safety of nalmefene for the treatment of alcohol use disorder: an update.</article-title>
              <source>Expert Opin Drug Saf</source>
              <year>2020</year>
              <volume>19</volume>
              <fpage>9</fpage>
              <lpage>17</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the safety of nalmefene as therapy of alcohol use disorders mentions that while &#x0201c;there is no evidence of hepatotoxicity associated with nalmefene, there is a lack of data involving patients with advanced liver disease&#x0201d;).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31868031</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Nalmefene.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Nalmefene+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Nalmefene: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Nalmefene">Trials on Nalmefene: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
